[go: up one dir, main page]

PE20221463A1 - Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer - Google Patents

Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer

Info

Publication number
PE20221463A1
PE20221463A1 PE2022000986A PE2022000986A PE20221463A1 PE 20221463 A1 PE20221463 A1 PE 20221463A1 PE 2022000986 A PE2022000986 A PE 2022000986A PE 2022000986 A PE2022000986 A PE 2022000986A PE 20221463 A1 PE20221463 A1 PE 20221463A1
Authority
PE
Peru
Prior art keywords
eso
cancer
treatment
fragment
polynucleotide encoding
Prior art date
Application number
PE2022000986A
Other languages
English (en)
Inventor
Ayaka AKIBA
Tatsuya Okudaira
Yasuhide MASUHARA
Keisuke Ohsumi
Shinichiro Fujii
Original Assignee
Astellas Pharma Inc
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Riken filed Critical Astellas Pharma Inc
Publication of PE20221463A1 publication Critical patent/PE20221463A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a una celula vector adyuvante artificial (aAVC) que expresan de manera estable y elevada NY-ESO-1 (celulas escamosas esofagicas de New York 1) o un fragmento de esta, como antigeno de cancer. Una celula de origen humano que comprende un polinucleotido que codifica CD1d y un polinucleotido que codifica NY-ESO-1 o un fragmento de esta, donde el polinucleotido que codifica NY-ESO-1 o un fragmento de esta esta operativamente ligado a un promotor inducible. Tambien refiere a una composicion farmaceutica que comprende dicha celula para el tratamiento de pacientes con cancer que expresa NY-ESO-1.
PE2022000986A 2019-12-02 2020-12-01 Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer PE20221463A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019217704 2019-12-02
PCT/JP2020/044586 WO2021112055A1 (ja) 2019-12-02 2020-12-01 がんの処置に用いるｎｙ－ｅｓｏ－１含有人工アジュバントベクター細胞

Publications (1)

Publication Number Publication Date
PE20221463A1 true PE20221463A1 (es) 2022-09-21

Family

ID=76222293

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000986A PE20221463A1 (es) 2019-12-02 2020-12-01 Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer

Country Status (21)

Country Link
US (2) US11672851B2 (es)
EP (1) EP4071240A4 (es)
JP (1) JP7646213B2 (es)
KR (1) KR20220119030A (es)
CN (1) CN114787344A (es)
AR (1) AR120648A1 (es)
AU (1) AU2020394993A1 (es)
BR (1) BR112022010763A2 (es)
CA (1) CA3162277A1 (es)
CL (1) CL2022001459A1 (es)
CO (1) CO2022008738A2 (es)
CR (1) CR20220320A (es)
DO (1) DOP2022000108A (es)
EC (1) ECSP22049399A (es)
IL (1) IL293482A (es)
JO (1) JOP20220121A1 (es)
MX (1) MX2022006716A (es)
PE (1) PE20221463A1 (es)
PH (1) PH12022551334A1 (es)
TW (1) TW202134431A (es)
WO (1) WO2021112055A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
WO2025230010A1 (ja) * 2024-05-02 2025-11-06 国立研究開発法人理化学研究所 ＣＤ１ｄ導入前にＣＤ１ｄリガンドでインキュベートされた細胞

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1990410T (lt) 2006-02-22 2020-03-10 Riken Imunoterapija, panaudojant ląstelę, gebančią koekspresuoti tikslinį antigeną ir cd1d, ir kuri buvo aktyvinta cd1d ligandu
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
WO2008057795A2 (en) * 2006-10-27 2008-05-15 Temple University - Of The Commonwealth System Of Higher Education Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera
CA2678618C (en) * 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
EP2371945A4 (en) * 2008-11-28 2013-01-16 Riken IMMUNOTHERAPY PROCEDURE WITH CD1d AND TARGETANT CO-EXPRESSIVE ALLO CELLS
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
BR112012024375A2 (pt) 2010-03-25 2016-05-24 3M Innovative Properties Co camada compósita
JPWO2013018778A1 (ja) 2011-07-29 2015-03-05 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
US10293058B2 (en) * 2015-04-22 2019-05-21 Curevac Ag RNA containing composition for treatment of tumor diseases
AU2016303662A1 (en) 2015-07-31 2018-02-22 Synlogic Operating Company, Inc. Bacteria engineered to treat disorders involving propionate catabolism
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
EP3595715A1 (en) * 2017-03-17 2020-01-22 CureVac AG Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy

Also Published As

Publication number Publication date
MX2022006716A (es) 2022-09-12
EP4071240A4 (en) 2024-01-17
PH12022551334A1 (en) 2023-11-20
EP4071240A1 (en) 2022-10-12
WO2021112055A1 (ja) 2021-06-10
CA3162277A1 (en) 2021-06-10
JPWO2021112055A1 (es) 2021-06-10
US20230000965A1 (en) 2023-01-05
CN114787344A (zh) 2022-07-22
KR20220119030A (ko) 2022-08-26
BR112022010763A2 (pt) 2022-08-23
JOP20220121A1 (ar) 2023-01-30
TW202134431A (zh) 2021-09-16
US20230330200A1 (en) 2023-10-19
AU2020394993A1 (en) 2022-06-09
CR20220320A (es) 2022-11-03
IL293482A (en) 2022-08-01
CL2022001459A1 (es) 2023-02-24
JP7646213B2 (ja) 2025-03-17
CO2022008738A2 (es) 2022-07-19
ECSP22049399A (es) 2022-08-31
AR120648A1 (es) 2022-03-09
US11672851B2 (en) 2023-06-13
DOP2022000108A (es) 2022-10-31

Similar Documents

Publication Publication Date Title
BR112017001183A2 (pt) tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CL2023003017A1 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
MX2021002292A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
MX386249B (es) Terapia tusc2 para usarse en el tratamiento de cáncer.
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
PE20221463A1 (es) Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer
MX2024000276A (es) Analogo de peptido de oxintomodulina acilado.
EA201992562A1 (ru) Пептиды для лечения сахарного диабета
CO2019003865A2 (es) Proteína terapéutica
MX2018014049A (es) Dihidrotestosterona y derivados y promotores de dihidrotestosterona en el tratamiento del cancer.
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX421742B (es) Composiciones y métodos para usarse en terapia génica empleando plásmidos, vectores y vectores no virales que contienen pcbp1 y/o mutantes de pcbp1 útiles para el tratamiento de enfermedades hiperproliferativas